Mediwound (NASDAQ:MDWD) Receives Buy Rating from HC Wainwright

Share on StockTwits

Mediwound (NASDAQ:MDWD)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Wednesday, AnalystRatings.com reports. They presently have a $5.50 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 105.99% from the stock’s current price.

A number of other research analysts have also recently commented on the company. Oppenheimer restated a “buy” rating and issued a $7.00 price target on shares of Mediwound in a research report on Tuesday. Zacks Investment Research raised Mediwound from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Saturday, June 20th.

Shares of NASDAQ MDWD opened at $2.67 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.89 and a current ratio of 3.08. Mediwound has a 52 week low of $1.44 and a 52 week high of $4.14. The stock has a market capitalization of $72.63 million, a P/E ratio of 11.13 and a beta of 1.41. The stock’s fifty day moving average is $2.17 and its 200 day moving average is $2.42.

Mediwound (NASDAQ:MDWD) last issued its quarterly earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.05. Mediwound had a negative return on equity of 75.91% and a net margin of 18.46%. The company had revenue of $4.44 million for the quarter, compared to analysts’ expectations of $4.25 million. Equities research analysts forecast that Mediwound will post -0.41 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC boosted its stake in Mediwound by 42.0% in the fourth quarter. Renaissance Technologies LLC now owns 407,408 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 120,508 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Mediwound by 136.4% during the first quarter. Acadian Asset Management LLC now owns 130,072 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 75,045 shares in the last quarter. Fortis Advisors LLC acquired a new stake in shares of Mediwound during the first quarter valued at about $108,000. Sargent Investment Group LLC boosted its stake in shares of Mediwound by 51.5% during the first quarter. Sargent Investment Group LLC now owns 117,400 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 39,900 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Mediwound by 15.8% during the first quarter. Wells Fargo & Company MN now owns 219,386 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 29,911 shares in the last quarter. 22.86% of the stock is currently owned by institutional investors and hedge funds.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: Most Active Stocks: Dollar Volume vs Share Volume

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Surface Oncology Inc  Shares Sold by Squarepoint Ops LLC
Surface Oncology Inc Shares Sold by Squarepoint Ops LLC
Deutsche Bank AG Acquires 13,770 Shares of Fiesta Restaurant Group Inc
Deutsche Bank AG Acquires 13,770 Shares of Fiesta Restaurant Group Inc
Squarepoint Ops LLC Reduces Stock Holdings in Fluidigm Co.
Squarepoint Ops LLC Reduces Stock Holdings in Fluidigm Co.
10,000 Shares in Fluidigm Co.  Acquired by FNY Investment Advisers LLC
10,000 Shares in Fluidigm Co. Acquired by FNY Investment Advisers LLC
Deutsche Bank AG Has $133,000 Stock Holdings in Fluidigm Co.
Deutsche Bank AG Has $133,000 Stock Holdings in Fluidigm Co.
Yamana Gold Inc.  Shares Sold by Hexavest Inc.
Yamana Gold Inc. Shares Sold by Hexavest Inc.


© 2006-2020 Ticker Report